Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor escape mechanisms in prostate cancer
Ashley M. Miller, Pavel Pisa
Cancer Immunology Immunotherapy (2005) Vol. 56, Iss. 1, pp. 81-87
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
Jemima Escamilla, Shiruyeh Schokrpur, Connie Liu, et al.
Cancer Research (2015) Vol. 75, Iss. 6, pp. 950-962
Open Access | Times Cited: 193
Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer
Stanimir Vuk‐Pavlović, Peggy A. Bulur, Yi Lin, et al.
The Prostate (2009) Vol. 70, Iss. 4, pp. 443-455
Open Access | Times Cited: 260
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
Philippe O. Gannon, Alexis Poisson, Nathalie Delvoye, et al.
Journal of Immunological Methods (2009) Vol. 348, Iss. 1-2, pp. 9-17
Closed Access | Times Cited: 238
Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression
Andreia Matos, Marcos Carvalho, Manuel Bicho, et al.
Nutrients (2021) Vol. 13, Iss. 12, pp. 4503-4503
Open Access | Times Cited: 61
Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach
Mahshad Entezam, Mohammad‐Javad Sanaei, Yousef Mirzaei, et al.
Life Sciences (2023) Vol. 318, pp. 121459-121459
Closed Access | Times Cited: 27
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer
Mengdie Wang, Christi Wisniewski, Choua Xiong, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 694
Closed Access | Times Cited: 24
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
Kathleen Ebelt, Gregor Babaryka, Bernhard Frankenberger, et al.
European Journal of Cancer (2009) Vol. 45, Iss. 9, pp. 1664-1672
Closed Access | Times Cited: 126
Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions
Marie Lundholm, Christina Hägglöf, Maria L. Wikberg, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 88
Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
Harm Westdorp, Annette E. Sköld, Berit A. Snijer, et al.
Frontiers in Immunology (2014) Vol. 5
Open Access | Times Cited: 87
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
Per Kongsted, Troels Holz Borch, Eva Ellebæk, et al.
Cytotherapy (2017) Vol. 19, Iss. 4, pp. 500-513
Closed Access | Times Cited: 74
Prostate cancer-specific hallmarks of amino acids metabolism: Towards a paradigm of precision medicine
Vladislav Strmiska, Petr Michálek, Tomáš Eckschlager, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2019) Vol. 1871, Iss. 2, pp. 248-258
Closed Access | Times Cited: 59
Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines
Yuqian Liu, Reyaj Mikrani, Dianyou Xie, et al.
Fundamental and Clinical Pharmacology (2019) Vol. 34, Iss. 2, pp. 160-172
Open Access | Times Cited: 55
iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells
Matteo Bellone, Monica Ceccon, Matteo Grioni, et al.
PLoS ONE (2010) Vol. 5, Iss. 1, pp. e8646-e8646
Open Access | Times Cited: 68
Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
Chantal Mengus, Clémentine Le Magnen, Emanuele Trella, et al.
Journal of Translational Medicine (2011) Vol. 9, Iss. 1
Open Access | Times Cited: 66
Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+PD-L1+phenotype in prostate cancer
Lisa K. Spary, Josephine Salimu, Jason Webber, et al.
OncoImmunology (2014) Vol. 3, Iss. 9, pp. e955331-e955331
Open Access | Times Cited: 65
Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison
Davide Brusa, Mariagrazia Simone, Paolo Gontero, et al.
International Journal of Urology (2013) Vol. 20, Iss. 10, pp. 971-978
Closed Access | Times Cited: 57
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
Jennifer L. Kalina, David S. Neilson, Alexandra P. Comber, et al.
Cancers (2017) Vol. 9, Iss. 2, pp. 13-13
Open Access | Times Cited: 50
Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells
Elena Degl’Innocenti, Matteo Grioni, Giusy Capuano, et al.
Cancer Research (2008) Vol. 68, Iss. 1, pp. 292-300
Open Access | Times Cited: 62
Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
Philippe O. Gannon, Jessica Godin-Ethier, Matthew Hassler, et al.
PLoS ONE (2010) Vol. 5, Iss. 8, pp. e12107-e12107
Open Access | Times Cited: 56
FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer
Sabina Davidsson, Ove Andrén, Anna‐Lena Ohlson, et al.
The Prostate (2017) Vol. 78, Iss. 1, pp. 40-47
Open Access | Times Cited: 42
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients
Katalin Balázs, Lilla Antal, Géza Sáfrány, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 4, pp. 296-296
Open Access | Times Cited: 28
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
Yael S. Barach, Jun Sik Lee, Xingxing Zang
Trends in Molecular Medicine (2010) Vol. 17, Iss. 1, pp. 47-55
Open Access | Times Cited: 48
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting
Andrew Gray, Adam B. Raff, Maurizio Chiriva‐Internati, et al.
Immunological Reviews (2008) Vol. 222, Iss. 1, pp. 316-327
Closed Access | Times Cited: 47
Immunogenicity of 56°C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells
Davide Brusa, Elisa Migliore, Stefano Garetto, et al.
The Prostate (2009) Vol. 69, Iss. 12, pp. 1343-1352
Closed Access | Times Cited: 44
Immunotherapy for Castration-Resistant Prostate Cancer
Guru Sonpavde, Philip W. Kantoff
Urologic Clinics of North America (2012) Vol. 39, Iss. 4, pp. 465-481
Closed Access | Times Cited: 37
Page 1 - Next Page

Scroll to top